The irreproducibility of scientific research has received attention in the Wall Street Journal, Science, Nature, and many other outlets, including editorials and presentations from the leaders of the NIH and the FDA.  In both the spring and fall 2012 HRA Members’ Meetings, speakers discussed the forces operating in science that sometimes fail to reinforce good scientific practice.  Bias, selective reporting, retractions. Insufficient statistical powering of studies, and outright fraud have been critical issues for HRA member organizations seeking to accelerate the development of treatments and cures since at least 2012 and unfortunately still remain at play today.

To address this systemic problem, a group of HRA members have formed the Research Reproducibility Interest Group.  The goal of this group is to develop concrete recommendations that nonprofit funding organizations can implement to ensure increased publication of reproducible scientific findings.  Resources from inside and outside HRA, as well as products this group develops, will be posted to this page.

If you are interested in being part of this important effort, please email Annette.


Best Practices of Biomedical Research:
Improving Reproducibility and Transparency of Preclinical Research Co-sponsored by the National Library of Medicine (NLM), Friends of the NLM, and Research!America
June 9-10, 2016
A discussion about challenges with non-reproducible research; highlighting positive strategies to achieve significant quality improvement in preclinical research studies.

Executive Summary can be found here

Slides from all presentations:

Robert M. Califf, MD, Commissioner, U.S. Food and Drug Administration
Title:  Expectations of Reproducible Research

Tara A. Schwetz, PhD, Special Assistant to the Principal Deputy Director, National Institutes of Health
Title:  Enhancing Reproducibility and Transparency of Research Findings

Andrew Balas, MD, PhD, Professor, Augusta University, Georgia
Title:   Quality and productivity in biomedical research

Eric Rubin, MD, Vice President, Global Clinical Oncology, Merck Research Laboratories
Title:   Due Diligence in Acquiring Science

Anthony M. Boccanfuso, Ph.D. Executive Director, University‐Industry Demonstration Partnership; The National Academies 
Title:  Expectations of Reproducible Research

Ivan Oransky, MD, Co-Founder, Retraction Watch  
Title:  When Misconduct Falls Through The Cracks: Institutional Responsibility

Ulrich Dirnagl, MD, Professor, University of Medicine, Berlin
Title:  Institutions Must Do Their Part for Reproducibility

Mark Dwain Lindner, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health
Titles:  Assessing Therapeutic Potential in Preclinical Models: A Very Personal Experience

Arturo Casadevall, MD, PhD, Bloomberg Distinguished Professor, Molecular Microbiology & Immunology, John Hopkins Bloomberg School of Public Health
Title:  Ethics and Institutional Responsibilities

Michaela Torkar, PhD, Editorial Director, F1000Research
Title:  Better Reproducibility Through Open Science

Elizabeth Iorns, PhD, Founder, Science Exchange
Title:  Replication of Biomedical Studies

Stan Young, PhD, CEO of Omicsoft Corporation
Title:  Environmental Estrogens: fraud or faulty statistics?

Jon R. Lorsch, PhD, Director, National Institute of General Medical Sciences
Title: The “Reproducibility Problem:” Reproducibility of Data and Strength of Conclusions

Atul Butte, MD, PhD, Director, Institute for Computational Health Sciences, University of California, San Francisco
Title:  Thoughts on reproducibility

Ferric C. Fang, MD, Professor, University of Washington
Title:  PROMOTING RESEARCH RESPONSIBILITY: Lessons From Retracted Publications

Leonard P. Freedman, PhD, President, GBSI (Global Biology Standards Institute)
Title:  Closing the Reproducibility Gap with Standards and Best Practices

Lorenzo Refolo, PhD, NIH National Institute on Aging
Alzheimers’ Disease AlzPED (Alzheimer’s Pre-Clinical Efficacy Database development)
Title:  Improving the Rigor, Reproducibility and Translatability of Preclinical Research for Alzheimer’s Disease: The Alzheimer’s Disease Preclinical Efficacy Database- AlzPED

John Ioannidis, MD, DSc, Professor, Stanford University  (via video)
Title:  What should we seek with reproducible research?

Christopher Austin, MD, Director, NCATS
Title:  Transition From Preclinical to Clinical Research